Clinical Trials
15
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 27
- Registration Number
- NCT06418724
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
- Conditions
- Melanoma Brain Metastases
- Interventions
- Radiation: Hypofractionated stereotactic radiotherapy
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 46
- Registration Number
- NCT06163820
- Locations
- 🇦🇺
Alfred Health, Melbourne, Victoria, Australia
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
- Conditions
- Solid Organ Transplant RecipientsSkin Cancer
- Interventions
- Other: Placebo
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 146
- Registration Number
- NCT05860881
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺The Prince Charles Hospital, Chermside, Queensland, Australia
Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients
- Conditions
- MelanomaSkin CancerAnxiety and Fear
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 670
- Registration Number
- NCT04385732
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Newcastle Skin Check, Newcastle, New South Wales, Australia
🇦🇺Dermatology Clinical Trials Unit, Westmead Hospital, Sydney, New South Wales, Australia
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
- Conditions
- Neuroendocrine TumorsMerkel Cell Carcinoma, Stage IMerkel Cell Carcinoma, Stage IIMerkel Cell CarcinomaCarcinoma Neuroendocrine SkinMerkel Cell Carcinoma, Stage III
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 122
- Registration Number
- NCT04291885
- Locations
- 🇦🇺
Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
🇦🇺Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
🇦🇺Melanoma Institute Australia, Sydney, New South Wales, Australia
- Prev
- 1
- 2
- 3
- Next